STOCKS TELEGRAPH

Tag: NASD:SINT

  • Patent Approval Boosts Sintx Technologies (SINT) Shares During Pre-Hour Trading

    Patent Approval Boosts Sintx Technologies (SINT) Shares During Pre-Hour Trading

    Sintx Technologies, Inc. (NASDAQ: SINT) shares are experiencing a significant increase on the US stock charts today after the issuance of a newly granted patent. As of the last premarket check, SINT stock was surging 79.44% to trade at $5.06.

    Patent Approval Strengthens Market Position

    Sintx Technologies (SINT) announced that the United States Patent and Trademark Office (USPTO) has awarded the company with U.S. Patent No. 12,239,761. The patent is not only a major addition to its growing portfolio of intellectual property, but also confirms Sintx’s position as a leader in silicon nitride technology, a segment that is still advancing at a rapid pace.

    Advancing Biomedical Applications

    The patent focuses on modern developments in silicon nitride material synthesis, especially for biomedical applications. Silicon nitride’s antiviral, antibacterial, and biomechanical qualities have made it a popular material for next-generation medical implants, regenerative medicine, and advanced coating technologies.

    Innovation in Implant Technology

    Innovative techniques for combining silicon nitride with a variety of biomaterial substrates are presented by the recently patented technology. Biocompatibility and infection resistance, two critical components of medical implant function, are greatly enhanced by this development.

    According to Sintx Technologies, this development will increase the application of silicon nitride in important medical domains such as dental, spinal, orthopaedic, and craniomaxillofacial implants. In order to make sure that its solutions contribute to better surgical results and longer implant lifespans, Sintx keeps improving its unique technology via continuous research and development.

    Increasing the Portfolio of Intellectual Property

    The only FDA-registered producer of implantable silicon nitride, Sintx Technologies, has produced a wide variety of goods, including as monolithic ceramic implants, particulate-based coatings, composite materials, and microspheres. Sintx Technologies now has 17 U.S. patents issued and 84 more applications pending globally. The business is still dedicated to growing its portfolio of intellectual property and leading the way in biomedical engineering developments.

  • Pre-Market Buzz: Sintx Technologies (SINT) Stock Climbs Amid Share Buyback News

    Pre-Market Buzz: Sintx Technologies (SINT) Stock Climbs Amid Share Buyback News

    The stock price of Sintx Technologies, Inc. (NASDAQ: SINT) had a notable increase during the most recent pre-market session, rising 53.85% to $3.20. The company’s announcement of a stock repurchase program, approved by its board of directors, to repurchase up to $500,000 worth of outstanding common shares over the upcoming quarters is what led to this dramatic increase.

    This effort, which represents almost 20% of all shares, demonstrates Sintx’s commitment to increasing shareholder value and its faith in its strategic path.

    Enhancing Value for Shareholders Through Strategic Allocation

    The initiative to repurchase shares is in line with Sintx’s overarching plan to maximize its capital structure. The corporation wants to increase ownership stakes for current shareholders and boost earnings per share by reducing the total number of outstanding shares through share repurchasing.

    This decision, like that of its industry rivals, shows Sintx’s dedication to using its solid financial position to return value to shareholders. The company’s leadership emphasizes its conviction in Sintx’s unrealized potential and development trajectory, viewing the present market price as an opportunity.

    Refocusing on Medical Markets with High Growth

    With a focus on high-impact, long-term prospects in the medical device sector, Sintx has also started a strategic realignment. The firm aims to provide novel solutions for spinal fusion devices, orthopedic implants, and surgical instruments by utilizing the special qualities of its cutting-edge materials, especially silicon nitride. Recent collaborations with healthcare institutions and industry leaders aim to strengthen its position in this evolving market.

    Strategic Restructuring for Long-Term Growth

    In the third quarter of 2024, Sintx implemented significant changes to align its operations with its renewed focus. Notably, the company exited its armor division, incurring a $4.5 million one-time impairment charge. Additionally, in order to simplify operations and create a leaner, more cost-efficient structure, labor cutbacks were implemented.

    These steps are intended to efficiently reallocate resources, improving the business’s capacity to seek long-term expansion in the medical device industry. By prioritizing long-term value creation and strategic capital allocation, Sintx Technologies positions itself for a robust future in advancing medical innovations.

  • What Is Driving Sintx Technologies (SINT) Stock Higher Today?

    What Is Driving Sintx Technologies (SINT) Stock Higher Today?

    Sintx Technologies, Inc. (NASDAQ: SINT) has witnessed a notable rise in its stock value on the US charts following its achievement of compliance with the NASDAQ listing requirements. As of the last check during current-market session, SINT stock was up 9.57% to $5.04.

    Stock Market Resurgence

    After receiving confirmation from The Nasdaq on June 11, 2024, Sintx Technologies made a public announcement stating that it has complied with the $1.00 minimum bid price threshold required to remain listed on The Nasdaq Capital Market. As a result, the previously pending listing issue has been resolved.

    Nevertheless, Sintx Technologies will remain under a “Mandatory Panel Monitor” for one year from the date of compliance. Should the company fail to maintain a minimum $1.00 closing bid price for 30 consecutive business days within this period, Nasdaq will initiate delisting procedures without granting an additional grace period to regain compliance. In such a scenario, Sintx Technologies retains the right to request a new hearing to address the deficiency.

    Strategic Contract Acquisition

    In a significant development, Sintx Technologies’ wholly-owned subsidiary, Technology Assessment and Transfer, Inc. (TA&T), has secured a three-month, $75,000 Phase I Small Business Innovation Research (SBIR) contract from AFWERX. This contract, focusing on the Enhanced Sinterability of Complex-Shaped 3D Printed Silicon Nitride (Si3N4), aims to overcome material challenges in propulsion and guidance technologies for next-generation high-temperature Department of the Air Force systems.

    Through this partnership, TA&T aims to enhance its innovative capabilities to bolster United States defense. Success in this initial phase may pave the way for TA&T/Sintx Technologies to secure a Phase II AFWERX contract valued at up to $1.25 million over 21 months.

    Pioneering 3D Printing In Silicon Nitride

    Sintx Technologies is addressing a critical gap in the industry: while there is considerable activity in 3D printing complex shapes of silicon nitride, there remains a lack of demonstrated production of silicon nitride parts that meet specific performance and repeatability standards. Leveraging its extensive experience with the silicon nitride material family and TA&T’s expertise in ceramic 3D printing, Sintx Technologies is uniquely positioned to lead advancements in this field.